Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).

Arndt Stahler,Volker Heinemann,Veronika Schuster,Annabel Helga Sophie Alig,Laura Elisabeth Fischer,Lena Weiss,Kathrin Heinrich,Annika Kurreck,Ivan Jelas,Jobst C. von Einem,Clemens Giessen-Jung,Ludwig Fischer von Weikersthal,Ursula Vehling-Kaiser,Thomas Decker,Jens Neumann,Thomas Kirchner,Andreas Jung,Joerg Kumbrink,Sebastian Stintzing,Dominik Paul Modest

Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).

2021

3552Background: Prognostic biomarkers beside RAS/BRAF status are necessary to identify metastatic colorectal cancer (mCRC) patients who benefit from combined (COMB) versus sequential (SEQ) treatmen...

Keywords:

Bevacizumab
Oncology
Treatment intensity
Biomarker (medicine)
Internal medicine
Medicine
Colorectal cancer
Irinotecan

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations